

Provider Bulletin



News and Information

January 13, 2022

Updated Prior Authorization Criteria for Drugs on the UCare Individual & Family Plans and UCare Individual & Family Plans with M Health Fairview Plans Formulary

On March 1, 2022, prior authorization criteria for the drugs listed below will be updated. These changes will be reflected in the [2022 Prior Authorization Criteria](#) document.

[Click here](#) to see updated criteria effective March 1, 2022.

[Pharmacy resources](#) are available on the UCare Provider website.

- Actemra
- Cimzia
- Daurismo
- Eligard
- Enbrel
- Gonadotropin-Releasing Hormone Agonists – Injectable Long-Acting Products
- Humira
- Iron Chelators
- Lemtrada
- Otezla
- Revcovi
- Rinvoq
- Skyrizi
- Stelara
- Taltz
- Trelstar
- Tremfya
- Triptodur
- Xeljanz
- Xospata
- Zejula
- Zytiga